Instem (LSE:INS) Insider Ownership : 13.11 % (As of Jun. 10, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Instem Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Instem's insider ownership is 13.11%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Instem's Institutional Ownership is 33.36%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Instem's Float Percentage Of Total Shares Outstanding is 0.00%.

Instem Insider Ownership Historical Data

The historical data trend for Instem's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instem Insider Ownership Chart

Instem Historical Data

The historical data trend for Instem can be seen below:

	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30
Insider Ownership	9.75	9.73	9.73	9.73	9.73	9.68	9.67	9.67	9.67	13.11

Instem Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Instem (LSE:INS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Instem PLC (LSE:INS) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

Diamond Way, Stone Business Park, Stone, Staffordshire, GBR, ST15 0SD

Website

https://www.instem.com

Instem PLC acts as a supplier of IT applications and technology-enabled outsourced services to the global health and life sciences community. Its segments include Study Management, Regulatory Solutions, and In Silico Solutions, Clinical Trial Acceleration. The company generates maximum revenue from Study Management. Geographically, it derives a majority of its revenue from the United States and also has a presence in the Europe and Rest of the World. Its portfolio of software solutions includes Instem Cloud, SEND Data Conversion, KnowledgeScan, SENDReady Consulting, Solution Deployment, Validation, Data Management, and Regulatory Information Management.

Instem (LSE:INS) Headlines

No Headlines